The Highland Opportunities and Income Fund announced a monthly distribution of $0.0385 per share, payable on October 30, 2026, to shareholders recorded by October 23, 2026. The closed-end fund invests in a mix of real estate-related securities, loans, bonds, and other instruments aiming for capital growth and income. Investors should note the distribution may include a return of capital and that the fund involves risks such as credit, real estate market fluctuations, and investment illiquidity. The fund is managed by NexPoint Asset Management and is designed primarily for long-term investors.
The Highland Opportunities and Income Fund announced a regular monthly distribution, with data context from Pluang as of Oct 02, 2026 03:41 WIB. For readers following US stocks, here is Pluang's market snapshot: out of 150 priced US stocks, 72 rose and 78 fell. Notable movers include Salesforce Inc (CRM) at USD 236.94 with a 3.21% increase, Roblox Corp (RBLX) at USD 42.38 up 2.89%, and International Business Machines Corp (IBM) at USD 226.08 rising 2.80%.
Wells Fargo initiated coverage on BlackRock with an 'Overweight' rating, highlighting it as a good entry point for investors. Analysts expect BlackRock's Q3 earnings per share to rise to $14.25 from $11.55 a year ago, with revenue projected at $7.56 ...
Nike reported earnings per share of $0.48, beating estimates, but revenue fell short at $11.21 billion due to weak demand in Greater China and rising competition. The company issued a cautious fiscal 2027 outlook with EPS forecast between $1.15 and $...
NETSOL Technologies reported a record $20.7 million revenue in fiscal 2026 Q4, with net income rising 45.9% to $3.8 million. The company improved its gross margin to 63.6% and operating margin to 21.6%, reflecting enhanced profitability. For fiscal 2...
On October 1, 2026, Nexalin Technology surged 76.4% after securing a 10-year exclusive deal for its medical device in South America. Armada Acquisition Corp. II jumped 42.9% following shareholder approval of its merger with Evernorth, expected to clo...
Jefferies analyst Roger Song set a $150 price target for Nektar Therapeutics, suggesting a 219% upside from its $46.99 trading price. This comes after Nektar presented positive six-month Phase IIb trial results for its alopecia drug REZPEG, which als...
